SSH.COM
7.6.2019 09:02:04 CEST | Business Wire | Press release
SSH.COM today announced that their access management gateway solution, PrivX , is now available for free in limited host environments to give IT and software teams all over the world the opportunity to enjoy the benefits of lean, scalable and automated access management to hybrid and multi-cloud (AWS, GCP, Azure, OpenStack) servers and applications.
Cloudification has changed the face of software development and deployment and IT management; modern techniques in software delivery require that trusted access management is in lockstep with development cycles, such as those used in the Continuous Integration/Continuous Delivery (CI/CD) models, while servers are located across on-prem, virtual private cloud (VPC) and multi-cloud environments. Extra steps, bottlenecks and manual processes simply don’t fit into that equation; it’s all about elasticity and automation.
SSH.COM’s Chief Customer Officer, Sami Ahvenniemi: “Spurred on by the shift to the cloud, we have identified that many our customers are looking for the following types of solutions:
- Modern and lean administrative access management tools
- Zero Trust solutions that manage access to critical assets, inside the perimeter
- Automated, scalable alternatives to in-house jump hosts and VPNs
- Centralized 3rd party access controls with monitoring and session recording
The focus is now on the entire access lifecycle of employees, including new hires, people moving around the organization, and people leaving the company. For example, developers, admins and external contractors are all needed - often temporarily - for various tasks with different levels of privilege, all within the critical IT infrastructure. Further, companies and teams often want to start small and scale IT management tools as needed, without taking on the burden of massive IT projects or turning their infrastructure into a hard-to-maintain and complex system. With PrivX, they get an access management solution that deploys in a matter of days, practically updates itself, provides monitoring of access traffic and delivers a simple user experience.”
SSH.COM’s PrivX offers just-in-time role-based access controls to multi-cloud and on-premises resources in development and production environments. Access authorization is never permanent but is based on short-lived certificates that expire within a few minutes of establishing the RDP/SSH connection. PrviX is an agentless and credentialess solution that integrates with existing identity access management (IAM) and directory service (AD/LDAP) tools as well as cloud-hosted servers and applications, including auto-discovery of cloud hosts.
SSH.COM is now making PrivX available free of charge online . Companies can start small and scale with PrivX as their business needs grow.
Mr. Ahvenniemi continued, “Cloud and hybrid environments require technological solutions that emphasize speed and agility over legacy products that are patched up to fit the needs of the cloud. That is why we built PrivX.”
Learn more about PrivX:
- Visit our PrivX product page .
- Download the PrivX datasheet .
- PrivX is reviewed in Kuppinger Cole’s Executive View Report .
- Read about PrivX and its ephemeral certificate-based authentication in our white paper .
About SSH.COM
SSH.COM helps organizations access, secure and control their digital core – their critical data, applications and services. We have over 3,000 customers around the world, including 40 percent of Fortune 500 companies, many of the world’s largest financial institutions, and major organizations in all verticals. We are committed to helping our customers thrive in the cloud era with solutions that offer secure access with zero inertia, zero friction and zero credentials risk. SSH.COM sells online; through offices in North America, Europe and Asia; and through a global network of certified partners. The company’s shares (SSH1V) are quoted on the NASDAQ Helsinki. For more information, visit www.ssh.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190607005053/en/
Contact:
SSH.COM Contact : Simo Karkkulainen SSH.COM +358 40 738 9406 simo.karkkulainen@ssh.com SSH.COM Agency Contact : Hanah Johnson March Communications +1 617-960-8892 ssh@marchcomms.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom